Table 7.
Pharmacokinetic parameters of six compounds after oral administration of the ZSS aqueous extract to normal control (NC) rats and insomnia model (IM) rats (mean ± SD, n = 6).
| Compound | Group | Cmax (ng/mL) | Tmax (h) | T1/2 (h) | AUC0-t (μg/L･h) | AUC0-∞ (μg/L･h) | CL (L/h/kg) |
|---|---|---|---|---|---|---|---|
| Coclaurine | NC | 1.98 ± 0.82 | 0.27 ± 0.09 | 0.45 ± 0.17 | 1.08 ± 0.30 | 1.13 ± 0.27 | 5929.56 ± 1470.63 |
| IM | 2.48 ± 0.98 | 0.23 ± 0.09 | 0.41 ± 0.28 | 0.91 ± 0.26 | 0.93 ± 0.28 | 7530.09 ± 2863.14 | |
| Magnoflorine | NC | 40.56 ± 12.67 | 0.30 ± 0.14 | 3.17 ± 1.97 | 54.56 ± 21.90 | 69.51 ± 28.52 | 1503.58 ± 589.55 |
| IM | 35.07 ± 13.68 | 0.20 ± 0.07 | 2.69 ± 1.28 | 45.13 ± 24.46 | 51.87 ± 23.75 | 2080.67 ± 891.30 | |
| Spinosin | NC | 45.22 ± 7.94 | 0.30 ± 0.14 | 3.01 ± 0.90 | 61.14 ± 22.16 | 79.94 ± 37.79 | 548.74 ± 183.96 |
| IM | 40.08 ± 17.46 | 0.23 ± 0.09 | 2.75 ± 0.92 | 38.31 ± 22.27 | 44.65 ± 23.96 | 1099.25 ± 570.61 | |
| 6‴-Feruloylspinosin | NC | 15.83 ± 1.54## | 0.30 ± 0.14 | 1.87 ± 1.10 | 20.95 ± 5.55# | 23.50 ± 6.42# | 928.92 ± 309.06# |
| IM | 12.65 ± 4.03 | 0.17 ± 0.00 | 1.39 ± 0.48 | 7.24 ± 4.71∗∗ | 7.41 ± 4.66∗∗ | 3485.60 ± 1543.52∗∗ | |
| Jujuboside A | NC | 19.44 ± 7.98 | 1.02 ± 0.61 | 1.94 ± 0.50 | 49.47 ± 24.94 | 55.94 ± 27.17 | 266.21 ± 136.94 |
| IM | 19.69 ± 10.03 | 0.52 ± 0.10∗ | 3.75 ± 1.52∗ | 58.55 ± 35.40 | 81.19 ± 47.73 | 233.09 ± 186.12 | |
| Jujuboside B | NC | 6.13 ± 1.36 | 0.43 ± 0.09 | 2.60 ± 0.92 | 10.18 ± 3.90 | 12.55 ± 5.39 | 682.30 ± 313.15▲ |
| IM | 7.59 ± 3.31 | 0.27 ± 0.09∗ | 2.10 ± 1.06 | 10.68 ± 4.04 | 12.33 ± 5.07 | 678.50 ± 287.71 |
#P < 0.05, ##P < 0.01 6‴-feruloylspinosin vs spinosin in NC rats; ▲P < 0.05 jujuboside B vs jujuboside A in NC rats; ∗P < 0.05, ∗∗P < 0.01 IM rats vs NC rats.